Covid-19 Antibody Responses in Cystic Fibrosis (CAR-CF)
Details
- Therapeutic approach
- Other
- Trial status
- Open to recruitment Participating Centres
- Trials Tracker ID
- TT007531
- Last updated
- 25/05/2022
Covid-19 Antibody Responses in Cystic Fibrosis (CAR-CF)
Study detailsCoronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or whether pwCF have protective genetic/immune factors.
This study aims to prospectively assess the proportion of pwCF, including both adults and children with CF who have evidence of SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this has on their CF disease.
The proposed study will recruit pwCF from paediatric and adult CF centres throughout the UK and other countries in Europe, Canada and the US.
- Phase
- Not applicable
- Length of participation
- 2 years
- Recruitment target
- 1000
- CF sponsor
- ECFS-CTN
Who can take part?
- Age range
- Any age
- Including people
Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study
Get in touch